Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 2, 2016, Pages 512-518

  Dubey, Anand Prakash ^a   Agarkhedkar, Sharad ^b   Chhatwal, Jugesh ^c   Narayan, Arun ^d   Ganguly, Satyabrata ^e   Wartel, T Anh ^f   Bouckenooghe, Alain ^f   Menezes, Josemund ^f  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

^b HOSPITAL AND RESEARCH CENTRE   (India)

^c CHRISTIAN MEDICAL COLLEGE   (India)

^d M S RAMAIAH MEDICAL COLLEGE   (India)

^e MEDICAL COLLEGE AND HOSPITAL   (India)

^f Research Development Procter Gamble   (Singapore)

Author keywords

CYD vaccine; dengue; immunogenicity; India; live attenuated vaccine; phase II trial; recombinant; safety; tetravalent dengue vaccine

Indexed keywords

DENGUE VACCINE; PLACEBO; LIVE VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ERYTHEMA; FEMALE; HUMAN; IMMUNOGENICITY; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAPULAR RASH; PHASE 2 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SERODIAGNOSIS; SWELLING; ADOLESCENT; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; INDIA; MIDDLE AGED; SECONDARY IMMUNIZATION; SEROCONVERSION; VACCINATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DENGUE; DENGUE VACCINES; DENGUE VIRUS; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; INDIA; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; PLACEBOS; SEROCONVERSION; VACCINATION; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 84960965384     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1076598     Document Type: Article

References (24)

1. World Health Organization. Global strategy for dengue prevention and control: 2012–2020. Available from: http://www.who.int/denguecontrol/9789241504034/en/ (Accessed 7July2014) 2012
2. National Vector Borne Disease Control Programme. Dengue cases and deaths in the country since 2008. : http://nvbdcp.gov.in/den-cd.html (Accessed 7July2014) 2014
3. A.Chakravarti, R.Arora, C.Luxemburger. Fifty years of dengue in India. Trans R Soc Trop Med Hyg 2012; 106:273-82.; PMID:22357401; http://dx.doi.org/10.1016/j.trstmh.2011.12.007
4. Government of India. Guidelines for Clinical Management of Dengue Fever, Dengue Haemorrhagic Fever and Dengue Shock Syndrome. : http://www.nvbdcp.gov.in/Doc/Clinical%20Guidelines.pdf (Accessed 7July2014) 2008
5. P.Garg, J.Nagpal, P.Khairnar, S.L.Seneviratne. Economic burden of dengue infections in India. Trans R Soc Trop Med Hyg 2008; 102:570-7; PMID:18402995; http://dx.doi.org/10.1016/j.trstmh.2008.02.015
6. M.A.Rai, H.Khan. Dengue: Indian subcontinent in the line of fire. J Clin Virol 2007; 38:269-70; PMID:17254843; http://dx.doi.org/10.1016/j.jcv.2006.12.010
7. M.Kakkar. Dengue fever is massively under-reported in India, hampering our response. BMJ 2012; 345:e8574; PMID:23255584; http://dx.doi.org/10.1136/bmj.e8574
8. D.S.Shepard, Y.A.Halasa, B.K.Tyagi, S.V.Adhish, D.Nandan, K.S.Karthiga, V.Chellaswamy, M.Gaba, N.K.Arora, INCLEN Study Group. Economic and disease burden of dengue illness in india. Am J Trop Med Hyg 2014;91:1235-42; PMID:25294616; http://dx.doi.org/10.4269/ajtmh.14-0002
9. S.Bhatt, P.W.Gething, O.J.Brady, J.P.Messina, A.W.Farlow, C.L.Moyes, J.M.Drake, J.S.Brownstein, A.G.Hoen, O.Sankoh, et al. The global distribution and burden of dengue. Nature 2013; 496:504-7; PMID:23563266; http://dx.doi.org/10.1038/nature12060
10. R.Z.Capeding, I.A.Luna, E.Bomasang, S.Lupisan, J.Lang, R.Forrat, A.Wartel, D.Crevat. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine 2011; 29:3863-72; PMID:21477675; http://dx.doi.org/10.1016/j.vaccine.2011.03.057
11. A.Sabchareon, D.Wallace, C.Sirivichayakul, K.Limkittikul, P.Chanthavanich, S.Suvannadabba, V.Jiwariyavej, W.Dulyachai, K.Pengsaa, T.A.Wartel, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380:1559-67; PMID:22975340; http://dx.doi.org/10.1016/S0140-6736(12)61428-7
12. M.R.Capeding, N.H.Tran, S.R.Hadinegoro, H.I.Ismail, T.Chotpitayasunondh, M.N.Chua, C.Q.Luong, K.Rusmil, D.N.Wirawan, R.Nallusamy, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014; 384:1358-65; PMID:25018116; http://dx.doi.org/10.1016/S0140-6736(14)61060-6
13. L.Villar, G.H.Dayan, J.L.Arredondo-Garcia, D.M.Rivera, R.Cunha, C.Deseda, H.Reynales, M.S.Costa, J.O.Morales-Ramirez, G.Carrasquilla, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015; 372:113-23; PMID:25365753; http://dx.doi.org/10.1056/NEJMoa1411037
14. A.S.Hss, M.T.Koh, K.K.Tan, L.G.Chan, L.Zhou, A.Bouckenooghe, D.Crevat, Y.Hutagalung. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study. Vaccine 2013; 31:5814-21; PMID:24135573; http://dx.doi.org/10.1016/j.vaccine.2013.10.013
15. N.H.Tran, C.Q.Luong, T.Q.H.Vu, J.Lang, Q.D.Vu, A.Bouckenooghe, T.A.Wartel. Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD- TDV) in healthy Vietnamese adults and children. J Vaccines Vaccin 2012; 3:162
16. Y.S.Leo, A.Wilder-Smith, S.Archuleta, L.P.Shek, C.Y.Chong, H.N.Leong, C.Y.Low, M.L.Oh, A.Bouckenooghe, T.A.Wartel, et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore. Hum Vaccin Immunother 2012; 8:1259-71; PMID:22894958; http://dx.doi.org/10.4161/hv.21224
17. K.B.Anderson, R.V.Gibbons, D.A.Cummings, A.Nisalak, S.Green, D.H.Libraty, R.G.Jarman, A.Srikiatkhachorn, M.P.Mammen, B.Darunee, et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis 2014; 209:360-8; PMID:23964110; http://dx.doi.org/10.1093/infdis/jit436
18. P.Bhoomiboonchoo, A.Nisalak, N.Chansatiporn, I.K.Yoon, S.Kalayanarooj, M.Thipayamongkolgul, T.Endy, A.L.Rothman, S.Green, A.Srikiatkhachorn, et al. Sequential dengue virus infections detected in active and passive surveillance programs in Thailand, 1994-2010. BMC Public Health 2015; 15:250; PMID:25886528; http://dx.doi.org/10.1186/s12889-015-1590-z
19. M.G.Guzman, G.Kouri, L.Valdes, J.Bravo, S.Vazquez, S.B.Halstead. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salud Publica 2002; 11:223-7; PMID:12049030; http://dx.doi.org/10.1590/S1020-49892002000400003
20. S.B.Halstead. Identifying protective dengue vaccines: guide to mastering an empirical process. Vaccine 2013; 31:4501-7; PMID:23896423; http://dx.doi.org/10.1016/j.vaccine.2013.06.079
21. M.R.Capeding, T.M.Laot, M.Boaz, T.A.Wartel, D.Crevat. Immunogenicity and safety of a tetravalent dengue vaccine during a five-year follow-up period. Trials in Vaccinology 2015; 4:19-23; http://dx.doi.org/10.1016/j.trivac.2015.03.002
22. M.Qiao, D.Shaw, R.Forrat, A.Wartel-Tram, J.Lang. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am J T rop Med Hyg 2011; 85:724-31; http://dx.doi.org/10.4269/ajtmh.2011.10-0436
23. G.H.Dayan, P.Garbes, F.Noriega, A.D.Izoton de Sadovsky, P.M.Rodrigues, C.Giuberti, R.Dietze. Immunogenicity and Safety of a Recombinant Tetravalent Dengue Vaccine in Children and Adolescents Ages 9-16 Years in Brazil. Am J Trop Med Hyg 2013; 89:1058-65; PMID:24189367; http://dx.doi.org/10.4269/ajtmh.13-0304
24. Torresi J, Heron LG, Qiao M, Marjason J, Chambonneau L, Bouckenooghe A, Boaz M, van der Vliet D, Wallace D, Hutagalung Y, Nissen MD, Richmond PC. Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study. 2015 Aug 13. pii: S0264-410X(15)01122-6; http://dx.doi.org/10.1016/j.vaccine.2015.08.008